Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation

Toxicology Letters

Volumn 176, Issue 2, 2008, Pages 104-123

  Besse, Jean Philippe ^a   Garric, Jeanne ^a  

^a CEMAGREF   (France)

Author keywords

Exposure; Metabolites; Pharmaceuticals; Pharmacology; Prioritization

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALENDRONIC ACID; ALLOPURINOL; ALPRAZOLAM; AMIODARONE; AMLODIPINE; AMOXICILLIN; AMPHOTERICIN B; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANXIOLYTIC AGENT; ATENOLOL; ATORVASTATIN; AZITHROMYCIN; BACLOFEN; BENFLUOREX; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; SURFACE WATER; UNINDEXED DRUG;

AQUATIC ENVIRONMENT; ARTICLE; CARCINOGENICITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENVIRONMENTAL IMPACT ASSESSMENT; ENZYME REGULATION; FRANCE; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; WATER CONTAMINATION;

ANIMALS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; FRANCE; GUIDELINES AS TOPIC; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; WATER POLLUTANTS, CHEMICAL;

EID: 37549008799     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2007.10.012     Document Type: Article

References (83)

1. AFSSAPS, 2006. Agence Française de Sécurité Sanitaire des Produits de Santé, personal communication.
2. Andreozzi R., Caprio V., Ciniglia C., De Champdore M., Lo Giudice R., Marotta R., and Zuccato E. Antibiotics in the environment: occurrence in Italian STPs, fate, and preliminary assessment on algal toxicity of amoxicillin. Environ. Sci. Technol. 38 (2004) 6832-6838
3. Ankley G.T., Jensen K.M., Kahl M.D., Makynen E.A., Blake L.S., Greene K.J., Johnson R.D., and Villeneuve D.L. Ketoconazole in the fathead minnow (Pimephales promelas): reproductive toxicity and biological compensation. Environ. Toxicol. Chem. 26 (2007) 1214-1223
4. Ashton D., Hilton M., and Thomas K.V. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci. Total Environ. 333 (2004) 167-184
5. Basly J.P., and Canivenc M.C.C. Dietary phytoestrogens: potential selective estrogen enzyme modulators?. Planta Med. 71 (2005) 1-8
6. BCB, 2006. Banque Claude Bernard. http://www.resip.fr. Last accessed 29/06/07.
7. Bendz D., Paxeus N.A., Ginn T.R., and Loge F.J. Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Höje River in Sweden. J. Hazard. Mater. 122 (2005) 195-204
8. Besse, J.P., Kausch-Barreto, C., Garric J., Exposure assessment of pharmaceuticals and their metabolites in the aquatic environment. Application to the French situation and preliminary prioritization. J. Human Ecol. Risk Assess., in press.
9. Britvic S., and Kurelec B. The effect of inhibitor of multixenobiotic resistance mechanism on the production of mutagens by Dreissena polymorpha in waters spiked with premutagens. Aquat. Toxicol. 47 (1999) 107-116
10. Brooks B.W., Turner P.K., Stanley J.K., Weston J.J., Glidewell E.A., Foran C.M., Slattery M., La Point T.W., and Huggett D.B. Waterborne and sediment toxicity of fluoxetine to select organisms. Chemosphere 52 (2003) 135-142
11. Budzinski H., and Togola A. Présence des résidus de médicaments dans les différents compartiments du milieu aquatique. Environnement Risques et Santé 5 (2006) 248-252
12. Carlsson C., Johansson A.-K., Alvan G., Bergman K., and Kühler T. Are pharmaceuticals potent environmental pollutants?: Part I: Environmental risk assessments of selected active pharmaceutical ingredients. Sci. Total Environ. 364 (2006) 67-87
13. Cha Y.I., Kim S.H., Solnica-Krezel L., and DuBois R.N. Cyclooxygenase-1 signaling is required for vascular tube formation during development. Dev. Biol. 282 (2005) 274-283
14. Chang H., Hu J., and Shao B. Occurrence of natural and synthetic glucocorticoids in sewage treatment plants and receiving river waters. Environ. Sci. Technol. 41 (2007) 3462-3468
15. Ciolino H.P., Wang T.T., Chao Y., and Yeh G. Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect Cytochrome P450 1A1 activity. Cancer Res. 58 (1998) 2754-2760
16. Crane M., Watts C., and Boucard T. Chronic aquatic environmental risks from exposure to human pharmaceuticals. Sci. Total Environ. 367 (2006) 23-41
17. Dahlström M., Jonsson P.R., Lausmaa J., Arnebrant T., Sjögren M., Holmberg K., Mårtensson L.G.E., and Elwing H. Impact of polymer surface affinity of novel antifouling agents. Biotechnol. Bioeng. 86 (2004) 1-8
18. Debernard S., Rossignol F., and Couillaud F. HMG-CoA reductase inhibitor fluvastatin inhibits insect juvenile-hormone biosynthesis. Gen. Comp. Endocrinol. 95 (1994) 92-98
19. Dorosz. P. (Ed), 2002. Guide Pratique des Médicaments, 22 ed. Maloine, Paris, France.
20. Drugs.com. Available at http://www.drugs.com. Last accessed 29/06/07.
21. Dzialowski E.M., Turner P.K., and Brooks B.W. Physiological and reproductive effects of beta adrenergic receptor antagonists in Daphnia magna. Arch. Environ. Contam. Toxicol. 50 (2006) 503-510
22. Eguchi K., Nagase H., Ozawa M., Endoh Y.S., Goto K., Hirata K., Miyamoto K., and Yoshimura H. Evaluation of antimicrobial agents for veterinary use in the ecotoxicity test using microalgae. Chemosphere 57 (2004) 1733-1738
23. EMEA, 2006. European Medicine Agency Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. EMEA/CHMP/SWP/4447/00.
24. Endicoot J.A., and Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58 (1989) 137-171
25. EU TGD Technical Guidance Document, 2003. Technical Guidance Document in support of Council Directive 93/67/EEC on risk Assessment for New Notified Substances and Commission Regulation (EC) 1488/94 on Risk Assessment for Existing Substances. Office for Official Publications of the European Communities, Luxembourg.
26. FDA, 1998. Guidance for Industry-Environmental Assessment of Human Drugs and Biologic Applications. FDA, CDER/CBER, CMC 6, rev. 1.
27. FDA-CDER, 1996. Retrospective Review of Ecotoxicity Data Submitted in Environmental Assessments. FDA Center for Drug Evaluation and Research, Rockville, MD, USA (Docket No. 96N-0057).
28. Fent K., Weston A.A., and Caminada D. Ecotoxicology of human pharmaceuticals. Aquat. Toxicol. 76 (2006) 122-159
29. Ferrari B., Mons R., Vollat B., Fraysse B., Paxéus N., Lo Giudice R., Pollio A., and Garric J. Environmental risk assessment of six human pharmaceuticals: Are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment?. Environ. Toxicol. Chem. 23 (2004) 1344-1354
30. Flaherty C.M., and Dodson S.I. Effects of pharmaceuticals on Daphnia survival, growth, and reproduction. Chemosphere 61 (2005) 200-207
31. Flippin J.L., Huggett D., and Foran C.M. Changes in the timing of reproduction following chronic exposure to ibuprofen in Japanese medaka, Oryzias latipes. Aquat. Toxicol. 81 (2007) 73-78
32. Fong P.P. Zebra mussel spawning is induced in low cocnetrations of putative serotonin re-uptake inhibitors (SSRIs). J. Exp. Zool. 280 (1998) 260-264
33. Foran C.M., Weston J., Slattery M., Brooks B.W., and Huggett D.B. Reproductive assessment of Japanese Medaka (Oryzias latipes) following a four-week fluoxetine (SSRI) exposure. Arch. Environ. Contam. Toxicol. 46 (2004) 511-517
34. Garric J., Ferrari B., Fraysse B., Mons R., and Vollat B. Impact de médicaments à usage humain sur les organismes aquatiques d'eau douce. Environnement Risques et Santé 5 (2006) 290-295
35. Guiguen Y., Baroiller J.F., Ricordel M.J., Iseki K., McMeel O.M., Martin S.A.M., and Fostier A. Involvement of estrogens in the process of sex differentiation in two fish species: the rainbow trout (Oncorhynchus mykiss) and a tilapia (Oreochromis niloticus). Mol. Reprod. Dev. 54 (1999) 154-162
36. Halling-Sørensen B., Nors Nielsen S., Lanzky P.F., Ingerslev F., Holten-Lützhøft H.C., and Jørgensen S.E. Occurrence, fate and effects of pharmaceutical substances in the environment-a review. Chemosphere 36 (1998) 357-393
37. Hardman, J.G., Limbird, L.E., Goodman Gilman, A. (Eds.), 1996. The pharmacological Basis of Therapeutics, 9th ed. McGraw-Hill Professional, New York.
38. Henry T.B., Kwon J.W., Armbrust K.L., and Black M.C. Acute and chronic toxicity of five selective serotonin reuptake inhibitors in Ceriodaphnia dubia. Environ. Toxicol. Chem. 23 (2004) 2229-2233
39. Hirsch R., Ternes T., Haberer K., and Kratz K.L. Occurrence of antibiotics in the aquatic environment. Sci. Total Environ. 225 (1999) 109-118
40. Holten-Lützhøft H.C., Halling-Sørensen B., and Jørgensen S.E. Algal toxicity of antibacterial agents applied in Danish fish farming. Arch. Environ. Contam. Toxicol. 36 (1999) 1-6
41. Huggett D.B., Benson W.H., Chipman K., Cook J.C., Gray L.E., Kinter L.B., Meyerhoff R.D., and Trudeau V.L. Role of mammalian data in determining pharmaceutical responses in aquatic species. In: Williams R.T. (Ed). Human Pharmaceuticals, Assessing the Impacts on Aquatic Systems (2005), SETAC Press
42. Isidori M., Lavorgna M., Nardelli A., Pascarella L., and Parrella A. Toxic and genotoxic evaluation of six antibiotics on non-target organisms. Sci. Tot. Environ. 346 (2005) 87-98
43. Jjemba P.K. Excretion and ecotoxicity of pharmaceutical and personal care products in the environment. Ecotoxicol. Environ. Saf. 63 (2006) 113-130
44. Jones O.A.H., Voulvoulis N., and Lester J.N. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res. 36 (2002) 5013-5022
45. Kolpin D.W., Furlong E.T., Meyer M.T., Thurman E.M., Zaugg S.D., Barber L.B., and Buxton H.T. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ. Sci. Technol. 36 (2002) 1202-1211
46. Krazeisen A., Breitling R., Möller G., and Adamski J. Human 17beta-hydroxysteroid dehydrogenase type 5 is inhibited by dietary flavonoids. Adv. Exp. Med. Biol. 505 (2002) 151-161
47. Kümmerer, K., 2000. Drugs, diagnostic agents and disinfectants in wastewater and water-a review. Schriftenreihe des Vereins fur Wasser, Boden und Lufthygiene 105, 59-71.
48. Länge R., and Dietrich D. Environmental risk assessment of pharmaceutical drug substances-conceptual considerations. Toxicol. Lett. 131 (2002) 97-104
49. Langston W.J., Burt G.R., Chesman B.S., and Vane C.H. Partitioning, bioavailability and effects of oestrogens and xeno-oestrogens in the aquatic environment. J. Mar. Biol. Assoc. U.K. 85 (2005) 1-31
50. Marselos M., and Vainio H. Carcinogenic properties of pharmaceutical agents evaluated in the IARC Monographs programme. Carcinogenesis 12 (1991) 1751-1766
51. Mercure F., and Van Der Kraak G. Mechanisms of action of free arachidonic acid on ovarian steroid production in the goldfish. Gen. Comp. Endocrinol. 102 (1996) 130-140
52. Miège C., Favier M., Brosse C., Canler J.P., and Coquery M. Occurrence of betablockers in effluents of wastewater treatment plants from the Lyon area (France) and risk assessment for the downstream rivers. Talanta 70 (2006) 739-744
53. Mills L.J., and Chichester C. Review of evidence: Are endocrine-disrupting chemicals in the aquatic environment impacting fish populations?. Sci. Total Environ. 343 (2005) 1-34
54. Nickerson J.G., Dugan S.G., Drouin G., and Moon T.W. A putative beta-adrenoceptor from the rainbow trout (Oncorhynchus mykiss). Molecular characterisation and pharmacology. Eur. J. Biochem. 268 (2001) 6465-6472
55. Oaks J.L., Gilbert M., Virani M.Z., Watson R.T., Meteyer C.U., Rideout B.A., Shivaprasad H.L., Ahmed S., Chaudhry M.J.I., Arshad M., Mahmood S., Ali A., and Khan A.A. Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 427 (2004) 630-633
56. Owen S.F., Giltrow E., Huggett D.B., Hutchinson T.H., Saye J., Winter M.J., and Sumpter J.P. Comparative physiology, pharmacology and toxicology of β-blockers: mammals versus fish. Aquat. Toxicol. 82 (2007) 145-162
57. Paffoni C., Welte B., Gousailles M., and Montiel A. New molecules involved by the European directives: from wastewater to drinking water treatment plants [Nouvelles molécules mises en cause par les directives européennes: De la station d'épuration à l'usine de traitement d'eau potable]. Journal Européen d'Hydrologie 37 (2006) 21-38
58. PNSE, 2004. Plan National Santé Environnement. Ministère de la Santé et de la Protection sociale. Ministère de l'Écologie et du Développement durable. Ministère de l'Emploi, du Travail et de la Cohésion sociale. Ministère délégué à la Recherche. Available at http://www.sante.gouv.fr/htm/dossiers/pnse/rapport.pdf.
59. Robinson A.A., Belden J.B., and Lydy M.J. Toxicity of fluoroquinolone antibiotics to aquatic organisms. Environ. Toxicol. Chem. 24 (2005) 423-430
60. Ruuskanen J.O., Laurila J., Xhaard H., Rantanen V.V., Vuoriluoto K., Wurster S., Marjamäki A., Vainio M., Johnson M.S., and Scheinin M. Conserved structural, pharmacological and functional properties among the three human and five zebrafish alpha(2)-adrenoceptors. Br. J. Pharmacol. 144 (2005) 165-177
61. Schwaiger J., Ferling H., Mallow U., Wintermayr H., and Negele R.D. Toxic effects of the non-steroidal anti-inflammatory drug diclofenac. Part I: Histopathological alterations and bioaccumulation in rainbow trout. Aquat. Toxicol. 68 (2004) 141-150
62. Seiler J.P. Pharmacodynamic activity of drugs and ecotoxicology-can the two be connected?. Toxicol. Lett. 131 (2002) 105-115
63. Snyder R.D., and Greene J.W. A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 488 (2001) 151-169
64. Stegeman J.J., Brouwer M., Richard T.D.G., Förlin L., Fowler B.A., Sanders B.M., and van Veld P.A. Molecular responses to environmental contamination: enzyme and protein systems as indicators of chemical exposure and effect. In: Hugget R.J., and Kimerly R.A. (Eds). Biomarkers: Biochemical, Physiological and Histological Markers of Anthropogenic Stress (1992), Lewis Publishers, Chelsea, MI, USA 235-335
65. Stuer-Lauridsen F., Birkved M., Hansen L.P., Holten-Lützhøft H.-C., and Halling-Sørensen B. Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. Chemosphere 40 (2000) 783-793
66. Sweetman, S.C. (Ed.), 2002. Martindale, The Complete Drug Reference, 33 ed. Pharmaceutical Press, Great Britain.
67. Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Water Res. 32 (1998) 3245-3260
68. Thibaut R., Schnell S., and Porte C. The interference of pharmaceuticals with endogenous and xenobiotic metabolizing enzymes in carp liver: an in vitro study. Environ. Sci. Technol. 40 (2006) 5154-5460
69. Tolls J. Sorption of veterinary pharmaceuticals in soils: a review. Environ. Sci. Technol. 35 (2001) 3397-3406
70. Togola, A., Bristeau, S., Amalric, L., 2007. Occurrence of pharmaceuticals in aquatic systems of Loire-Brittany Basin (France). Poster communication. ERAPharm International Conference on Pharmaceuticals in the Environment. Lakeside Conference Centre, York, UK.
71. Toomey B.H., and Epel D. Multixenobiotic resistance in Urechis caupo embryos: protection from environmental toxins. Biol. Bull. 185 (1993) 355-364
72. Triebskorn R., Casper H., Heyd A., Eikemper R., Köhler H.R., and Schwaiger J. Toxic effects of the non-steroidal anti-inflammatory drug diclofenac: Part II. Cytological effects in liver, kidney, gills and intestine of rainbow trout (Oncorhynchus mykiss). Aquat. Toxicol. 68 (2004) 151-166
73. Turner J.E., Minkoff C.G., Martin K.H., Misra R., and Swenson K.I. Oocyte activation and passage through the metaphase/anaphase transition of the meiotic cell cycle is blocked in clams by inhibitors of HMG-CoA reductase activity. J. Cell. Biol. 128 (1995) 1145-1162
74. Trösken E.R., Scholz K., Lutz R.W., Volkel W., Zarn J.A., and Lutz W.K. Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr. Res. 30 (2004) 387-394
75. Trösken E.R., Fischer K., Völkel W., and Lutz W.K. Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation. Toxicology 219 (2006) 33-40
76. Tutundjian R., and Minier C. Les protéines de résistance multiple et leur exploitation pour la biosurveillance chez les organismes aquatiques. Regard sur la biochimie 4 (2002) 37-50
77. Vasskog T., Berger U., Samuelsen P.J., Kallenborn R., and Jensen E. Selective serotonin reuptake inhibitors in sewage influents and effluents from Tromsø, Norway. J. Chromatogr. A 1115 (2006) 187-195
78. ow: Key to understanding and regulating waste-water-derived contaminants. Environ. Chem. 3 (2006) 439-449
79. WHO, 2007. Collaborating Center for Drug Statistics Methodology. Complete ATC/DDD Index 2007. Available at http://www.whocc.no/atcddd/.
80. Wiegel S., Aulinger A., Brockmeyer R., Harms H., Löffler J., Reincke H., Schmidt R., Stachel B., Von Tümpling W., and Wanke A. Pharmaceuticals in the river Elbe and its tributaries. Chemosphere 57 (2004) 107-126
81. Williams M., Saison C.L.A., Williams D.B., and Kookana R.S. Can aquatic distribution of human pharmaceuticals be related to pharmacological data?. Chemosphere 65 (2006) 2253-2259
82. Yu J.T., Bouwer E.J., and Coelhan M. Occurrence and biodegradability studies of selected pharmaceuticals and personal care products in sewage effluent. Agric. Water Manag. 86 (2006) 72-80
83. Zuccato E., Castiglioni S., and Fanelli R. Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment. J. Hazard. Mater. 122 (2005) 205-209